Published August 10, 2026
The California Supreme Court ruled 6-1 on August 3, 2026 that drug manufacturers have no legal duty to develop and bring a safer alternative product to market faster than they choose to. The decision, in the consolidated Gilead Tenofovir Cases (No. S283862), resolved one specific legal theory raised by roughly 24,000 plaintiffs who took Gilead's HIV medication tenofovir disoproxil fumarate (TDF, sold as Truvada and Viread) — that Gilead unreasonably delayed releasing a similarly effective, less toxic alternative compound (TAF) in order to protect its existing TDF patent revenue.
Writing for the majority, Justice Joshua Groban held that because plaintiffs in this particular claim did not allege TDF itself was defectively designed, manufactured, or labeled, Gilead owed no duty of care in choosing when to commercialize a different, newer drug. The ruling reverses a 2024 California Court of Appeal decision that had allowed the "duty to innovate" theory to proceed.
The decision is significant, but it's narrower than some headlines suggest. It applies specifically to the "duty to innovate" negligence theory litigated in this coordinated proceeding (JCCP No. 4954, San Francisco County Superior Court). The much larger body of TDF/Truvada litigation — coordinated separately through a federal MDL in the Northern District of California and additional state court claims, together covering an estimated 26,000 pending cases — centers on different claims: that Gilead failed to adequately warn patients and doctors about TDF's own risks of kidney damage and bone density loss, and related design-defect, negligence, and fraud-by-omission theories. Those claims were not part of what the Supreme Court decided and continue to move through discovery and pretrial proceedings.
If you took Truvada, Viread, Atripla, or another TDF-based medication and later experienced kidney damage or significant bone density loss, see Atumio's Truvada/Viread case page to learn more about who may be affected.